Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.380
-0.060 (-1.74%)
Apr 7, 2026, 11:32 AM EDT - Market open
Cellectis Revenue
In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth. Cellectis had revenue of $12.21M in the quarter ending December 31, 2025, a decrease of -19.51%.
Revenue (ttm)
$79.59M
Revenue Growth
+61.72%
P/S Ratio
3.27
Revenue / Employee
$347,568
Employees
229
Market Cap
260.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 42.17M |
| Editas Medicine | 40.52M |
| Orchestra BioMed Holdings | 33.48M |
| Alector | 21.05M |
| Abeona Therapeutics | 5.82M |
| AC Immune | 4.51M |
| SAB Biotherapeutics | 114.70K |
CLLS News
- 17 days ago - Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ... - GuruFocus
- 17 days ago - Q4 2025 Cellectis SA Earnings Call Transcript - GuruFocus
- 18 days ago - Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 19 days ago - What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings - GuruFocus
- 25 days ago - Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - GlobeNewsWire
- 4 weeks ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 3 months ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 4 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire